Dr. Madan Maitre

AREA(S) OF INTEREST:

Head & neck cancers, Breast cancer, Gynaecological cancers, Prostate cancer, Neuro-oncology, Paediatric cancers, Re-irradiation, Oligometastases

PROCEDURES PERFORMED:

IG-IMRT, VMAT, SRS/SBRT, intracavitary and interstitial brachytherapy, total body irradiation (TBI), craniospinal irradiation (CSI), adaptive radiotherapy

TREATMENTS/PROCEDURES OFFERED:

SBRT (Spine, lung, prostate, oligometastases), SRS, Brachytherapy (cervix cancer, soft tissue sarcoma), Adaptive radiotherapy, Breath hold and motion management (breast cancer, lung cancer, liver and pancreatic cancer), IGRT and VMAT for all cancer sites

NAME OF INSTITUTE(S):

• Tata Memorial Hospital, Mumbai
• HomiBhabha National Institute (HBNI)

FELLOWSHIPS:

• Neuro-Oncology Fellowship, Brain Tumour Foundation of India, Tata Memorial Hospital, Mumbai
• Head and Neck Cancers Fellowship, IAEA HYPNO, ACTREC-Tata Memorial Hospital, Mumbai
• Paediatrics and Late Effects Fellowship, Peter MacCallum Cancer Centre and Royal Children’s Hospital, Melbourne, Australia

• Teenage and Young Adults (TYA) Gold Medal, ISNOCON2021
• ICRO-PRODVANCE "Masterclass in Radiosurgery’ 2020
• Research presentations at ISPNO 2018 (Denver, USA) and EANO 2018 (Stockholm, Sweden)
• Top-scoring research at ISNOCON 2018
• Sam Mistry grant for Oral Presentation of the MD dissertation at WFNOS 2017(Zurich, Switzerland)

Dr. Madan Maitre has trained comprehensively at Tata Memorial Hospital Mumbai in cancer management. He has gained experience in high-precision radiotherapy during his fellowships in India and Australia, including Gamma Knife, proton therapy, and re-irradiation. He has also served as an Assistant Professor at Tata Memorial Centre, participating in tumour boards for multi-disciplinary cancer care. He was instrumental in organising cancer survivorship clinic for brain tumour survivors.

His research on the late effects of radiation, quality of life, and re-irradiation has been presented at major international conferences and published in high-impact journals.

Dr. Madan Maitre is passionate about radiotherapy outcomes in cancer survivors, especially teenagers and young adults. He is keenly interested in developing models to minimise the late treatment effects and has contributed to several research papers and book chapters in leading publications. His research has focused on neurocognition, neuro-endocrine effects, and re-irradiation safety in recurrent cancers.

PUBLICATIONS

• High-dose salvage re-irradiation in recurrent/progressive adult diffuse gliomas: development of a novel prognostic scoring system. Maitre M, Gupta T, Maitre P et al. Cancer/Radiotherapie2022
• Magnetic Resonance Imaging in the Contemporary Management of Medulloblastoma: Currentand Emerging Applications. Dasgupta, A., Maitre, M., Pungavkar, S., & Gupta, T.Medulloblastoma, 187-214. (2022). Springer Books.
• Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies.Chatterjee, A., Maitre, M., Dasgupta, A., Sridhar, E., & Gupta, T. (2022). Medulloblastoma (pp.215-235). Humana, New York, NY.
• Prognostic impact of semantic MRI features on survival outcomes in molecularly subtypedmedulloblastoma. Dasgupta, A., Gupta, T., Maitre, M., Kalra, B., et al. (2022). Strahlentherapieund Onkologie, 2022 Mar;198(3):291-303. doi: 10.1007/s00066-021-01889-9.
• Prognostic Impact of Semantic MRI Features on Survival Outcomes in Medulloblastoma: DoesIt Reflect or Transcend Radiogenomic Correlation? Dasgupta, A., Gupta, T., Maitre, M., et al.(2021) [Pre-print: https://doi.org/10.21203/rs.3.rs-790721/v1]
• High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing orhurting? - Gupta T, Maitre M, Maitre P, et al. ClinTranslOncol. 2021 Feb 2. https://doi:10.1007/s12094-020-02526-0.
• Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose SalvageRe-irradiation. - Maitre P, Gupta T, Maitre M, et al. ClinOncol (R CollRadiol). 2021Mar;33(3):e155-e165. https://doi: 10.1016/j.clon.2020.08.011
• Clinical Audit of Survival Outcomes and Prognostic Factors in Adolescents and Adults with Medulloblastoma. Patil R, Gupta T, Maitre M, et al. J Adolesc Young Adult Oncol. 2021 doi: 10.1089/jayao.2021.0034.
• Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impactupon clinical outcomes in recurrent/progressive ependymoma. Gupta, T., Maitre, M., Gupta, P.,et al. (2020). Journal of neuro-oncology, 147(2), 405–415. https://doi.org/10.1007/s11060-020-03434-7
• Hippocampal radiotherapy dose-constraints for predicting long-term neurocognitive outcomes:Mature data from a prospective trial in young patients with brain tumors. Goda, J. S., Dutta, D.,Krishna, U., Goswami, S., Gupta, T., Kothavade, V., Kannan, S., Maitre, M., Bano, N., &Jalali,R. (2020). Neuro Oncol. 2020 Nov 26;22(11):1677-1685.https://doi.org/10.1093/neuonc/noaa076
• Dose-Constraint Model to Predict Neuroendocrine Dysfunction in Young Patients with BrainTumors: Data From a Prospective Study. - Jalali, R., Maitre, M., Gupta, T., et al (2019). PracticalRadiation Oncology, 9(4), e362–e371. https://doi.org/10.1016/j.prro.2019.02.011
• Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initialdiagnosis, primary risk-stratification, and molecular subgrouping. Gupta T, Maitre M, Sastri GJ,et al. J Neurooncol. 2019;144(2):283-291. https://doi.org/10.1007/s11060-019-03225-9
• 68Ga-prostate-specific membrane antigen PETCT-based response to androgen deprivationtherapy in patients with prostate cancer. Gupta, P., Murthy, V., Agarwal, A., Maitre, M., Mhatre,N., & Rangarajan, V. (2019). Nuclear medicine communications, 40(12), 1283–1288. https://doi.org/10.1097/MNM.0000000000001105

PROFESSIONAL MEMBERSHIPS

• Radiation Professional registration - Atomic Energy Regulatory Board
• Life member of the Association of Radiation Oncologists of (AROI)
• Life member, Maharashtra Chapter, Association of Radiation Oncologists of India
• Life Member of the Society of Neuro-Oncology (ISNO)